ABBV
stockAbbVie Inc. · Healthcare · Drug Manufacturers - General
Last price
US$ 291,31
▲ 1,07% on 06/11/2026FMP · on 06/11/2026
- Dividend yield 12m
- 2,34%4 payouts paid over 12 months ÷ close of 06/11 · FMP
- P/L
- 122,92price ÷ EPS · FMP · as of 31/12/2025
- P/VP
- —no data at the source
- 52 weeks
- 197,38294,89lowest and highest close · FMP
ABBV dividend yield math
Payouts paid from 08/11/2025 to 08/11/2026 (the source has no record date), divided by the official close.
| Record date | Payment | Type | Status | US$ per share |
|---|---|---|---|---|
| — | 14/08/2026 | Dividend | paid | 1,73 |
| — | 15/05/2026 | Dividend | paid | 1,73 |
| — | 17/02/2026 | Dividend | paid | 1,73 |
| — | 14/11/2025 | Dividend | paid | 1,64 |
| Sum ÷ close of 06/11/2026 (US$ 291,31) | US$ 6,83 ÷ US$ 291,31 = 2,34% | |||
Recent dividends
- 16/02/2027To be paid: Dividend of US$ 1,82
- 16/11/2026To be paid: Dividend of US$ 1,73
- 14/08/2026Paid: Dividend of US$ 1,73
- 15/05/2026Paid: Dividend of US$ 1,73
06/11/2026 · US$ 291,31
10/11/2025: US$ 218,71; 06/11/2026: US$ 291,31; mínima US$ 197,38, máxima US$ 294,89.
Fundamentals
Indicators
P/L
122,92
Relação entre o preço da ação e o lucro por ação (LPA) informado pela fonte de dados.
checkhide
- Source:
- Financial Modeling Prep
- Collected:
- 08/11/2026 · 09:05
- Calculation:
- = US$ 291,31 (price 06/11/2026 · quote source) ÷ US$ 2,37 (EPS 31/12/2025 · statements via FMP)
- Limitation:
- Compares price with reported earnings per share; moves with price daily and distorts when earnings are atypical.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
P/VP
—
Compara o preço de mercado de uma ação ou cota com o valor contábil/patrimonial por ação ou cota (VPA).
Dividend Yield
2,34%
Proventos da ação (ou rendimentos do FII) com data-com nos 365 dias anteriores ao cálculo, pagos ou já anunciados, em relação ao preço usado na coleta.
checkhide
- Source:
- FMP (dividends) + price
- Reference:
- 31/12/2025
- Calculation:
- = US$ 6,83 (12-month payouts · dividend history via FMP · 4 payouts in 12 months) ÷ US$ 291,31 (price 06/11/2026 · quote source)
- Limitation:
- Last 12 months of payouts ÷ price; moves with price and payouts may not repeat.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
Income history
Recent dividends
| Type | Ex-date | Payment date | Value/share |
|---|---|---|---|
| dividendo | — | 16/02/2027 | US$ 1,82 |
| dividendo | — | 16/11/2026 | US$ 1,73 |
| dividendo | — | 14/08/2026 | US$ 1,73 |
| dividendo | — | 15/05/2026 | US$ 1,73 |
| dividendo | — | 17/02/2026 | US$ 1,73 |
| dividendo | — | 14/11/2025 | US$ 1,64 |
| dividendo | — | 15/08/2025 | US$ 1,64 |
| dividendo | — | 15/05/2025 | US$ 1,64 |
| dividendo | — | 14/02/2025 | US$ 1,64 |
Context
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.